BRPI0413076A - método analìtico para composições de pancreatina e comparáveis - Google Patents

método analìtico para composições de pancreatina e comparáveis

Info

Publication number
BRPI0413076A
BRPI0413076A BRPI0413076-6A BRPI0413076A BRPI0413076A BR PI0413076 A BRPI0413076 A BR PI0413076A BR PI0413076 A BRPI0413076 A BR PI0413076A BR PI0413076 A BRPI0413076 A BR PI0413076A
Authority
BR
Brazil
Prior art keywords
pancreatin
analytical method
comparable compositions
enzyme mixtures
enzyme
Prior art date
Application number
BRPI0413076-6A
Other languages
English (en)
Inventor
Andreas Potthoff
Andreas Koerner
Bernd Thumbeck
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of BRPI0413076A publication Critical patent/BRPI0413076A/pt
Publication of BRPI0413076B1 publication Critical patent/BRPI0413076B1/pt
Publication of BRPI0413076B8 publication Critical patent/BRPI0413076B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/994—Pancreatin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO ANALìTICO PARA COMPOSIçõES DE PANCREATINA E COMPARáVEIS". A presente invenção refere-se a um novo processo para analisar a identidade e padrão peptídico elou protéico, bem como a estabilidade de amostras contendo misturas enzimáticas fisiologicamente aceitáveis com atividade lipolítica, proteolítica e amilolítica, mas, especialmente, de misturas de enzimas, tais como a pancreatina, em particular no contexto da produção de produtos medicinais compreendendo a referida mistura enzimática, por exemplo, pancreatina precipitada e/ou minimicroesferas de pancreatina.
BRPI0413076A 2003-07-29 2004-07-26 processo analítico para composições de pancreatina e comparáveis BRPI0413076B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49051003P 2003-07-29 2003-07-29
PCT/EP2004/008332 WO2005012911A1 (en) 2003-07-29 2004-07-26 Analytical method for pancreatin and comparable compositions

Publications (3)

Publication Number Publication Date
BRPI0413076A true BRPI0413076A (pt) 2006-10-03
BRPI0413076B1 BRPI0413076B1 (pt) 2016-06-28
BRPI0413076B8 BRPI0413076B8 (pt) 2021-07-27

Family

ID=34115404

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413076A BRPI0413076B8 (pt) 2003-07-29 2004-07-26 processo analítico para composições de pancreatina e comparáveis

Country Status (10)

Country Link
US (1) US7479378B2 (pt)
EP (1) EP1651962B1 (pt)
JP (1) JP4891766B2 (pt)
CN (1) CN1809753B (pt)
AU (1) AU2004260961B2 (pt)
BR (1) BRPI0413076B8 (pt)
CA (1) CA2528906C (pt)
MX (1) MXPA06001173A (pt)
RU (1) RU2359270C2 (pt)
WO (1) WO2005012911A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
DE602005009677D1 (de) * 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
RU2413532C2 (ru) * 2005-07-29 2011-03-10 Зольвай Фармасьютиклз Гмбх Способ получения стерилизованного порошкообразного панкреатина
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2007139989A2 (en) * 2006-05-26 2007-12-06 Brandeis University Tissue sample preparation, and maldi ms imaging thereof
NZ583699A (en) * 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
EP2318035B1 (en) * 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
ES2668909T3 (es) 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
JP5190422B2 (ja) * 2009-08-04 2013-04-24 ホーユー株式会社 等電点電気泳動用膨潤ゲルの作成方法
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
CN106310242B (zh) 2011-04-21 2020-02-28 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
US9291630B1 (en) 2011-08-29 2016-03-22 Scientific Protein Laboratories, Llc RP-HPLC method for the analysis and quantification of pancreatin active pharmaceutical agents
US9063034B1 (en) * 2011-10-17 2015-06-23 Scientific Protein Laboratories, Llc Determination of the absence or presence of Bacillus cereus enterotoxin via a western blot
US10151726B2 (en) 2011-11-14 2018-12-11 King Saud University Bioimaging nucleic acids, proteins and enzymes
US9677114B1 (en) * 2012-04-18 2017-06-13 Scientific Protein Laboratories, Llc Method for evaluating degradation pathways for pancreatin active pharmaceutical agents
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
CN103278453A (zh) * 2013-03-09 2013-09-04 青海省农林科学院 利用双向电泳和maldi-tof-ms技术获得小麦根相关抗旱蛋白的方法
CN105891303A (zh) * 2016-05-10 2016-08-24 江苏省农业科学院 利用双向电泳技术检测产琥珀酸放线杆菌中酶的方法
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
CN111220720B (zh) * 2019-12-05 2022-07-22 上海上药第一生化药业有限公司 胰蛋白酶及其酶原的纯度检测方法
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CA3188616A1 (en) * 2021-03-23 2022-09-29 Kashiv Biosciences, Llc Method for size based evalution of pancreatic protein mixture

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2512746C3 (de) * 1975-03-22 1980-04-24 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
EP0115023B1 (de) * 1982-12-30 1988-07-27 Nordmark Arzneimittel GmbH Verfahren zur Gewinnung von Pankreatin
JP2732515B2 (ja) * 1990-01-08 1998-03-30 ニカ ヘルス プロダクツ リミテッド リボヌクレアーゼ二量体の製造方法
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
GB9624927D0 (en) * 1996-11-29 1997-01-15 Oxford Glycosciences Uk Ltd Gels and their use
CA2309534A1 (en) * 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
CA2400484A1 (en) * 2000-02-08 2001-08-16 The Regents Of The University Of Michigan Protein separation and display
US6537434B1 (en) * 2000-07-21 2003-03-25 Large Scale Proteomics Corporation First dimension electrophoresis separation method and apparatus
US6905879B2 (en) * 2000-10-23 2005-06-14 Genetics Institute, Inc. Isotope-coded ionization-enhancing reagents (ICIER) for high-throughput protein identification and quantitation using matrix-assisted laser desorption ionization mass spectrometry
JP2003042956A (ja) * 2001-07-31 2003-02-13 Fuji Photo Film Co Ltd データの読み取り方法およびそれに用いるスキャナ
JP2003083893A (ja) * 2001-09-17 2003-03-19 Tadashi Matsunaga サブマイクロ粒子表面における蛍光測定法
JP2003194775A (ja) * 2001-12-28 2003-07-09 Japan Science & Technology Corp タンパク質の電気泳動法

Also Published As

Publication number Publication date
BRPI0413076B8 (pt) 2021-07-27
EP1651962B1 (en) 2013-09-11
JP2007500343A (ja) 2007-01-11
CN1809753B (zh) 2010-10-20
JP4891766B2 (ja) 2012-03-07
BRPI0413076B1 (pt) 2016-06-28
WO2005012911A1 (en) 2005-02-10
AU2004260961B2 (en) 2010-05-20
US20050112743A1 (en) 2005-05-26
MXPA06001173A (es) 2006-04-11
RU2359270C2 (ru) 2009-06-20
CN1809753A (zh) 2006-07-26
US7479378B2 (en) 2009-01-20
HK1091897A1 (en) 2007-01-26
CA2528906A1 (en) 2005-02-10
AU2004260961A1 (en) 2005-02-10
RU2006105780A (ru) 2007-09-10
CA2528906C (en) 2013-07-16
EP1651962A1 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
BRPI0413076A (pt) método analìtico para composições de pancreatina e comparáveis
Georgieva et al. Proteome analysis of snake venom toxins: pharmacological insights
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
Tan et al. Unveiling the elusive and exotic: Venomics of the Malayan blue coral snake (Calliophis bivirgata flaviceps)
Moura-da-Silva et al. Evidence for heterogeneous forms of the snake venom metalloproteinase jararhagin: a factor contributing to snake venom variability
UA89944C2 (ru) Продуцирование высокоманнозных белков в растительных культурах
PT1162995E (pt) Enzimas para o tratamento da diabetes mellitus do tipo i
BR0206521A (pt) Misturas de enzimas microbianas
PT910647E (pt) Variantes hiperactivas da dnase i humana
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
Helmerhorst et al. Identification of Lys-Pro-Gln as a novel cleavage site specificity of saliva-associated proteases
DE60042154D1 (de) Verwendung von lektin oder konjugaten zur modulation der c-fibre aktivität
Leonardi et al. Hemorrhagin VaH4, a covalent heterodimeric P-III metalloproteinase from Vipera ammodytes ammodytes with a potential antitumour activity
WO1999050439A3 (en) Anthrax lethal factor is a mapk kinase protease
Quintana et al. Stinging caterpillars from the genera Podalia, Leucanella and Lonomia in Misiones, Argentina: a preliminary comparative approach to understand their toxicity
Okamoto et al. PI class metalloproteinase from Bothrops moojeni venom is a post-proline cleaving peptidase with kininogenase activity: Insights into substrate selectivity and kinetic behavior
Sandesha et al. A comparative cross-reactivity and paraspecific neutralization study on Hypnale hypnale, Echis carinatus, and Daboia russelii monovalent and therapeutic polyvalent anti-venoms
BR0310003A (pt) compostos peptìdeos e seu uso como substratos de protease
DE69933551D1 (de) Menschliche protease und verwendung davon für pharmazeutischen anwendungen und zur reduktion der allergisierenden wirkung von nicht-menschlichen proteinen
Doolittle Clotting of mammalian fibrinogens by papain: a re-examination
BRPI0416434A (pt) métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina
ES2113878T3 (es) Proteina c hibrida.
ES2099714T3 (es) Procedimiento de tratamiento endoproteolitico de las proteinas (precursores) y de produccion microbiologica de proteinas.
Jurgilas et al. PO41, a snake venom metalloproteinase inhibitor isolated from Philander opossum serum
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ABBOTT PRODUCTS GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/06/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/07/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.